76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Avita Therapeutics Inc
Closed
6.09 6.47
Overview
Share price change
24h
Min
5.7
Max
6.27
Income | -2.3M -14M |
|---|---|
Sales | 108K 19M |
EPS | -0.826 |
Profit margin | -74.857 |
Employees | 260 |
EBITDA | -9.9M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +163.83% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | -84M 160M |
|---|---|
Previous open | -0.38 |
Previous close | 6.09 |
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
Avita Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Avita Therapeutics Inc Forecast
Price Target
By TipRanks
163.83% upside
12 Months Forecast
Average 15.17 USD 163.83%
High 19 USD
Low 12.5 USD
Based on 3 Wall Street analysts offering 12 month price targets forAvita Therapeutics Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Avita Therapeutics Inc
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
